Gefitinib vs Nivolumab

Gefitinib vs Nivolumab: Overview

This comparison examines the pharmacological differences between Gefitinib and Nivolumab.

Mechanism of Action

Gefitinib: Selective reversible inhibitor of EGFR tyrosine kinase.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Gefitinib — 48 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Gefitinib — C22H24ClFN4O3.

Molecular Weight: Gefitinib — 446.9000 g/mol.

Type: Gefitinib — Small molecule; Nivolumab — Antibody.